Literature DB >> 24971465

Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer.

Yifeng Fang1, Hong Yu1, Xiao Liang1, Junfen Xu2, Xiujun Cai1.   

Abstract

The high morbidity and mortality of colorectal cancer pose a significant public health problem worldwide. Here we assessed the pro-cancer efficacy and mechanism of action of CCNB1 in different colorectal cancer cells. We provided evidence that CCNB1 mRNA and protein level were upregulated in a subset of human colorectal tumors, and positively correlated with Chk1 expression. Repression of Chk1 caused a significant decrease in cell proliferation and CCNB1 protein expression in colorectal cancer cells. Furthermore, downregulation of CCNB1 impaired colorectal cancer proliferation in vitro and tumor growth in vivo. Specifically, suppression of CCNB1 caused a strong G 2/M phase arrest in both HCT116 and SW480 cells, interfering with the expression of cdc25c and CDK1. Additionally, CCNB1 inhibition induced apoptotic death in certain colorectal cancer cells. Together, these results suggest that CCNB1 is activated by Chk1, exerts its oncogenic role in colorectal cancer cells, and may play a key role in the development of a novel therapeutic approach against colorectal cancer.

Entities:  

Keywords:  CCNB1; Chk1; apoptosis; cell cycle; cell growth; colorectal cancer

Mesh:

Substances:

Year:  2014        PMID: 24971465      PMCID: PMC4128869          DOI: 10.4161/cbt.29691

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  34 in total

Review 1.  New insights into cyclins, CDKs, and cell cycle control.

Authors:  Irma Sánchez; Brian David Dynlacht
Journal:  Semin Cell Dev Biol       Date:  2005-06       Impact factor: 7.727

2.  Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

Authors:  Mayur A Gadhikar; Maria Rita Sciuto; Marcus Vinicius Ortega Alves; Curtis R Pickering; Abdullah A Osman; David M Neskey; Mei Zhao; Alison L Fitzgerald; Jeffrey N Myers; Mitchell J Frederick
Journal:  Mol Cancer Ther       Date:  2013-07-09       Impact factor: 6.261

3.  Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.

Authors:  Qinglei Gao; Xiaoyuan Huang; Duozhuang Tang; Yang Cao; Gang Chen; Yunping Lu; Liang Zhuang; Shixuan Wang; Gang Xu; Jianfeng Zhou; Ding Ma
Journal:  Apoptosis       Date:  2006-10       Impact factor: 4.677

4.  Prognostic value of cyclin B1 protein expression in colorectal cancer.

Authors:  Heike Grabsch; Kristina Lickvers; Olaf Hansen; Shinsuke Takeno; Reinhart Willers; Wolfgang Stock; Helmut E Gabbert; Wolfram Mueller
Journal:  Am J Clin Pathol       Date:  2004-10       Impact factor: 2.493

5.  Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.

Authors:  E Niméus-Malmström; A Koliadi; C Ahlin; M Holmqvist; L Holmberg; R-M Amini; K Jirström; F Wärnberg; C Blomqvist; M Fernö; M-L Fjällskog
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

Review 6.  The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.

Authors:  Ruth Thompson; Alan Eastman
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

7.  Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells.

Authors:  Juping Yuan; Ruilan Yan; Andrea Krämer; Frank Eckerdt; Marc Roller; Manfred Kaufmann; Klaus Strebhardt
Journal:  Oncogene       Date:  2004-07-29       Impact factor: 9.867

8.  Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase.

Authors:  T Izumi; J L Maller
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

9.  The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas.

Authors:  Lieve Verlinden; Isabelle Vanden Bempt; Guy Eelen; Maria Drijkoningen; Ilse Verlinden; Kathleen Marchal; Christiane De Wolf-Peeters; Marie-Rose Christiaens; Luc Michiels; Roger Bouillon; Annemieke Verstuyf
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

10.  Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection.

Authors:  Li Weng; Juan Du; Qinghui Zhou; Binbin Cheng; Jun Li; Denghai Zhang; Changquan Ling
Journal:  Mol Cancer       Date:  2012-06-08       Impact factor: 27.401

View more
  51 in total

1.  Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.

Authors:  Mingshan Niu; Yulong Chong; Yan Han; Xuejiao Liu
Journal:  Cancer Biol Ther       Date:  2015-05-21       Impact factor: 4.742

2.  Identification of critical genes in gastric cancer to predict prognosis using bioinformatics analysis methods.

Authors:  Jing Liu; Liang Ma; Zhiming Chen; Yao Song; Tinging Gu; Xianchen Liu; Hongyu Zhao; Ninghua Yao
Journal:  Ann Transl Med       Date:  2020-07

3.  Identification of key regulators associated with colon cancer prognosis and pathogenesis.

Authors:  Narges Toolabi; Fattane Sam Daliri; Amir Mokhlesi; Mahmood Talkhabi
Journal:  J Cell Commun Signal       Date:  2021-03-26       Impact factor: 5.782

4.  Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.

Authors:  Zhanzhan Xu; Yu Zhou; Yexuan Cao; Thi Lan Anh Dinh; Jing Wan; Min Zhao
Journal:  Med Oncol       Date:  2016-10-18       Impact factor: 3.064

5.  Cyclin b1 suppresses colorectal cancer invasion and metastasis by regulating e-cadherin.

Authors:  Yifeng Fang; Xiao Liang; Wenbin Jiang; Jianbo Li; Junfen Xu; Xiujun Cai
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

6.  NSun2 delays replicative senescence by repressing p27 (KIP1) translation and elevating CDK1 translation.

Authors:  Hao Tang; Xiuqin Fan; Junyue Xing; Zhenyun Liu; Bin Jiang; Yali Dou; Myriam Gorospe; Wengong Wang
Journal:  Aging (Albany NY)       Date:  2015-12       Impact factor: 5.682

7.  Novel direct AMPK activator suppresses non-small cell lung cancer through inhibition of lipid metabolism.

Authors:  Xi Chen; Chun Xie; Xing-Xing Fan; Ze-Bo Jiang; Vincent Kam-Wai Wong; Jia-Hui Xu; Xiao-Jun Yao; Liang Liu; Elaine Lai-Han Leung
Journal:  Oncotarget       Date:  2017-10-09

8.  CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker.

Authors:  Zhiqing Shen; Xueping Yu; Yijuan Zheng; Xueping Lai; Julan Li; Yuxiang Hong; Huatang Zhang; Chunlin Chen; Zhijun Su; Ruyi Guo
Journal:  Onco Targets Ther       Date:  2018-02-20       Impact factor: 4.147

9.  Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.

Authors:  Qian-Qian Zhang; Jian Chen; Da-Lei Zhou; You-Fa Duan; Cui-Ling Qi; Jiang-Chao Li; Xiao-Dong He; Min Zhang; Yong-Xia Yang; Lijing Wang
Journal:  Int J Biol Sci       Date:  2017-03-12       Impact factor: 6.580

10.  Hypermethylation of BEND5 contributes to cell proliferation and is a prognostic marker of colorectal cancer.

Authors:  Ruo-Kai Lin; Wan-Yu Hung; Yu-Fang Huang; Yu-Jia Chang; Chien-Hsing Lin; Wei-Yu Chen; Shih-Feng Chiu; Shih-Ching Chang; Shih-Feng Tsai
Journal:  Oncotarget       Date:  2017-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.